Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune and Complement-Mediated Disease Therapeutics.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CR1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CR1 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View CR1 Products |
| Gene Delivery | CR1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View CR1 Products |
| Benchmark Ab | Anti-CR1 (Sequence of Clinical Candidates) Recombinant positive control. |
View CR1 Products |
| Validator | CR1 siRNA Set For knockdown verification. |
View CR1 Products |
| Related Target A | CD55 Synergistic membrane-bound complement regulator that controls C3/C5 convertases. |
View CD55 Products |
| Related Target B | CD46 Cofactor protein working alongside CR1 in mediating Factor I cleavage of C3b/C4b. |
View CD46 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational integrity of large, highly repetitive structures (30 SCR domains) | HEK293 Expressed (Native Glycosylation) ensuring correct folding of long homologous repeats (LHRs) |
| Differentiating C3b vs. C4b binding domains | Domain-specific truncated proteins (LHR-A, B, C) strictly verified by theoretical MW and mass spec |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live CR1/CD35 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CR1/CD35 therapeutics is intensifying, with major players shifting focus from traditional systemic soluble CR1 (sCR1) proteins to tissue-targeted fusion proteins and bispecific antibodies. As first-generation therapies reach the clinic, the next wave of R&D is targeting localized complement regulation to avoid systemic immunosuppression, particularly in renal diseases and ischemia-reperfusion injury.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Soluble CR1 (sCR1) | Celldex Therapeutics, Adienne | Transplant Rejection, Glomerulonephritis | Binding Affinity & Kinetics (Need high-purity ECD-Fc for SPR) |
| Targeted Fusion Proteins | Appelis Pharmaceuticals, Q32 Bio | Kidney Diseases, AMD | Tissue-homing and binding competition assays (Need sequence-verified antigens) |
| Bispecific Antibodies | Academic Institutes, Biotech Startups | Autoimmune Diseases, SLE | Dual-targeting validation (Need stable cell lines via Lentivirus) |